CTO Nakayama Contributes Invited Article to Experimental Medicine, Japan’s Leading Life Science Journal, on AI-Driven Drug Discovery
2026/3/12
GEXVal Inc.March 12, 2026 CTO Nakayama Contributes Invited Article to Experimental Medicine Special Issue on A […]
Rare Disease Day Update: FRAXA Features GEXVal’s FRAXA-DVI Completion and FDA Orphan Drug Designation
2026/2/28
GEXVal Inc.February 28, 2026 FRAXA Research Foundation Features GEXVal's Completion of FRAXA-DVI Program and F […]
GEXVal Selected as Presenting Company at Biotech Showcase™ 2026
2026/1/7
GEXVal Inc.January 7, 2026 GEXVal Selected as Presenting Company at Biotech Showcase™ 2026 GEXVal Inc. (Presid […]
GEXVal Featured in BioCentury Article
2025/12/22
GEXVal Inc.December 22, 2025 GEXVal Featured in BioCentury Article “Raising the Sun: Japan Biotech Looks to Le […]
GEXVal Senior Director Speaks at University of Tokyo Hospital Drug Discovery Training Program
2025/12/12
GEXVal Inc.December 12, 2025 GEXVal Senior Director Delivers Lecture at University of Tokyo Hospital TR/Academ […]